-
A court in Seoul, South Korea, has denied a request by Kolon Life Science to suspend the government's decision to prohibit production and sale of its gene therapy Invossa, reported The Korea Herald.
-
Delivering the ruling, the court pointed out that Invossa's safety has not been fully guaranteed, while the ministry's measure is justifiable as the original permit was based on false reporting of a key ingredient.
-
Kolon Life Science initially received approval for the medication from South Korea's Ministry of Food and Drug Safety in 2017.
-
However, the approval was revoked earlier this year after the drugmaker was found to have falsely reported an ingredient used in Invossa and violated labeling rules.
To read more NewsPoints articles, click here.
